---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-066676"
form_type: "8-K"
ticker: "GRML"
cik: "0001907223"
company_name: "Greenland Mines Ltd"
filed_at: "2025-07-22T23:59:59+00:00"
generated_at: "2026-05-18T04:34:02.274987+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Klotho Neurosciences enters exclusive global gene therapy license with AAVnerGene

## Summary
- Exclusive global rights to AAVnerGene's AAVone platform for three gene therapy programs: KLTO-101, KLTO-202, KLTO-303.
- Initial license fees: $250,000 (first product) to $500,000 (third product); plus 2% royalty on revenue.
- Targets Alzheimer's, Parkinson's, ALS, motor neuron diseases, and aging-related pathologies.
- CEO cites faster, cheaper manufacturing with higher purity and lower toxicity via AAVone and ATHENA platforms.
- Partnership aims to accelerate clinical development and reduce high drug price/dose-related toxicity.

## SEC filing metadata
- accession: 0001213900-25-066676
- form_type: 8-K
- ticker: GRML
- cik: 0001907223
- company_name: Greenland Mines Ltd
- filed_at: 2025-07-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907223/000121390025066676/0001213900-25-066676-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907223/000121390025066676/ea0249890-8k_klotho.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-066676
- JSON: https://secwatch.observer/filing/0001213900-25-066676.json
- Plain text: https://secwatch.observer/filing/0001213900-25-066676.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.